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Lipids play animportant role as risk or protective factors in Alzheimer’s disease(AD), a disease biochemically characterized by the
accumulation of amyloid beta peptides (Aβ), released by proteolytic processing of the amyloid precursor protein (APP). Changes
in sphingolipid metabolism have been associated to the development of AD. The key enzyme in sphingolipid de novo synthesis is
serine-palmitoyl-CoA transferase (SPT). In the present study we identiﬁed a new physiological function of APP in sphingolipid
synthesis. The APP intracellular domain (AICD) was found to decrease the expression of the SPT subunit SPTLC2, the catalytic
subunit oftheSPTheterodimer, resulting inthatdecreased SPTactivity. AICDfunction wasdependent onFe65 andSPTLC2levels
are increased in APP knock-in mice missinga functional AICD domain. SPTLC2 levels are also increased in familial and sporadic
AD postmortem brains, suggesting that SPT is involved in AD pathology.
1.Introduction
Alzheimer’s disease (AD) is a devastating neurodegener-
ative disorder and the most common cause of dementia
in the elderly, clinically characterized by a progressive
loss of memory. Pathological hallmarks for AD are the
presence of amyloid plaques, composed of amyloid beta
peptides (Aβ), and neuroﬁbrillary tangles, which consist of
hyperphosphorylated tau proteins [1–3]. Aβ peptides are
released by sequential processing of the amyloid precursor
protein (APP), a large type-I transmembrane protein, by β-
and γ-secretases. The β-secretase BACE1 generates the N-
terminus of Aβ and a C-terminal stub of 99 amino acids
(aa), which is further cleaved by γ-secretase to release Aβ
and the intracellular domain of APP (AICD) [4–6]. The
γ-secretase represents a protein complex of at least four
proteins in which the presenilins constitute the active centre
o ft h ep r o t e a s e[ 7–10]. APP, BACE1 as well as Presenilin
1 (PS1), Presenilin 2 (PS2) and the other components of
the γ-secretase complex are all transmembrane proteins,
pointing towards a role of lipids, especially the lipid com-
position of cellular membranes, in the development of AD.
Several lipids, including cholesterol and the sphingolipids
sphingomyelin and ganglioside GM1, have been shown to
inﬂuence the generation of Aβ [11–13] and a deregulation
of sphingolipid metabolism was recently connected to AD2 International Journal of Alzheimer’s Disease
[12, 14]. The ﬁrst step involved in sphingolipid de novo
synthesis is the condensation of serine and palmitoyl-CoA
to generate 3-dehydrosphinganine, catalyzed by the enzyme
serine-palmitoyl transferase (SPT), which is suggested to be
the rate-limiting enzyme in sphingolipid synthesis (Figure 1)
[15]. 3-Dehydrosphinganine is further transformed to dihy-
droceramide, which is then desaturated to form ceramide,
the simplest sphingolipid. Ceramide can be converted to
sphingomyelin, sphingosine or various glycosphingolipids,
which are ubiquitous constituents of membrane lipids and
which are involved in various cellular events, including
signal transduction, proliferation, diﬀerentiation, apoptosis
and the maintenance of neuronal tissues and cells [16–
19]. Furthermore, sphingolipids along with cholesterol have
been shown to be required for the formation of detergent-
resistant membrane microdomains, also called rafts, which
are discussed to be the membrane microdomains where
amyloidogenic processing of APP preferentially occurs [20–
24].
2.Materialsand Methods
2.1. Cell Culture. SH-SY5Y, MEF PS1r, MEF PS1/2−/−,
MEF APPwt, MEF APP/APLP2−/− and MEF carrying
PS1 familial Alzheimer’s Disease mutations (E280A, A285V,
T354I) cells were cultivated in DMEM (Sigma, Taufkirchen,
G e r m a n y ) ,1 0 %F C S( P A NB i o t e c h ,A i d e n b a c h ,G e r m a n y ) .
ForPS1orPS-FAD/pCDNA3.1retransfected MEFPS1/2−/−
cells additional Zeocin (300μg/mL) (Invitrogen, Karlsruhe,
Germany) and for SH-SY5Y-FE65 Knock-down cells addi-
tional HygromycinB (400μg/mL) (PAN Biotech, Aidenbach,
Germany) was used.
2.2. Human and Murine Brain Material. Human FAD, SAD
and corresponding control brain samples were obtained
from Brain-Net(fordetailssee Tables 1 and 2 in Supplemen-
tary Materials available online at doi:10.4061/2011/695413).
Age- (+/− 3m o n t h s )a n dg e n d e r - m a t c h e dA P P −/− mice
brains and APP
￿CT15 mice brains and corresponding
controls have been described previously and at least 3 mice
brains of diﬀerent mice were analysed [25].
2.3. Determination of Peptides Eﬀects. To determine the
eﬀect of Aβ40 (10ng/mL) and Aβ42 (1ng/mL) (B. Penke,
Szeged, Hungary) or AICD (sequence in 1-letter code:
KMQQNGYENPTYKFFEQMQN) (2μM) (Genscript Cor-
poration, Piscatway, USA)synthetic peptides were incubated
for 6 days in cell culture. Detection of intracellular Aβ was
performed as described previously [26].
2.4. Knock-Down Experiments. According to the manufac-
turers protocol we used the SureSilencing shRNA Plas-
mid (SABioscience, Frederick, USA). The following insert
sequences were used to generate the Fe65 knock-down: 5 -
TCC CTG GAC CAC TCT AAA CTT-3 ;5  -CAA CCC AGG
GAT CAA GTG TTT-3 ;5  -AAG GCT TTG AGG ATG GAG
AAT-3 ;5  -TGT CCA CAC GTT TGC ATT CAT-3 .A s
control the following sequence was used: 5 -GGA ATC TCA
TTC GAT GCA TAC-3 .
2.5. Quantitative Real-Time PCR Experiments. Total RNA
was extracted from cells or tissue using TRIzol reagent
(Invitrogen, Karlsruhe, Germany), according to manufac-
turers’ protocols. 2μg total RNA were reverse-transcribed
using High Capacity cDNA Reverse Transcription Kits,
and quantitative real-time PCR analysis was carried out
using Fast SYBR Green Master Mix on 7500 Fast Real
Time PCR System (7500 Fast System SDS Software 1.3.1.;
Applied Biosystems, Darmstadt, Germany). Changes in gene
expression were calculated using 2-(ΔΔCt) method [27].
Results were normalized to β-actin. The following primer
sequences were used: murine:S p t l c 1 :5  -GCA GGA GCG
TTC TGATCTTA-3  and5 -CCGGAC ACGATGTTGTAG
TT-3 ;S p t l c 2 :5  -AAG TGC CAC CAT GCA ACA GA-3  and
5 -TTG GCT CCA GGC ACA CTA CA-3 ; β-Actin: 5 -CCT
AGG CAC CAG GGT GTG AT-3  and 5 -TCT CCA TGT
CGTCCCAGTTG
 ;human:Sptlc2:5  -TATGGAGCTGGA
GTG TGC AG-3  and 5 -GAATTC GTT GCA AATCCCAT-
3 ; β-Actin: 5 -CTT CCT GGG CAT GGA GTC-3  and 5 -
AGC ACT GTG TTG GCG TAC AG-3 .
2.6. Lipid Extraction. A modiﬁed Bligh and Dyer [28]
method was used to extract lipids to measure SPT activ-
ity as described below. After stopping the reaction by
adding 3,75mL CHCl3 :MeOH:HCl (1:2:0,06), mixture
was vortexed for 1h at room temperature (RT). Then
1,25mL CHCl3 was added and vortexed again for 1h at
RT. After adding 1,25mL CHCl3 and 1,25mL H2O, samples
were vortexed for another 10min before centrifugation
at 5000rpm for 10min. The phase containing lipids was
transferred to another glass tube and evaporated under
nitrogen-ﬂow at 30◦C. 1mL H2O was added to evapo-
rated lipids before another 3,75mL of CHCl3 :MeOH:HCl
(1:2:0,06) was added. The extraction cycle described
here was repeated one time and after ﬁnal evaporation
under nitrogen-ﬂow at 30◦C lipids were dissolved in
100μLC H C l 3.
2.7. Protein Determination. Protein determination was car-
ried out according to Smith et al. [29]. Brieﬂy, we used 20μL
of bovine serum albumin (Sigma, Taufkirchen, Germany)
for the standard curve in a concentration range of 0,1–
1,1μg/μL. 0,5–2μL of each sample was loaded onto a 96-
well plate (BD, Heidelberg, Germany) in triplicates. 200μL
of buﬀer (4% CuSO4:BCA-solution (Sigma, Taufkirchen,
Germany) (1:39)) was added to each well, and assay plate
was incubated for 15min at 37◦C and for another 15min at
RT. Absorbance was determined at a wavelength of 550nm
using a MultiscanEX (Thermo Fisher Scientiﬁc, Schwerte,
and Germany).
2.8. Determination of SPT Activity. For analysis of SPT
enzyme activity cells are harvested into 500μLb u ﬀer A
containing 100mM HEPES (Sigma, Taufkirchen, and Ger-
many) and 50μM pyridoxal phosphate (Sigma, Taufkirchen,International Journal of Alzheimer’s Disease 3
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Figure 1: Biosynthetic pathway of sphingolipid de novo synthesis.
Germany) supplemented with complete protease inhibitor,
and protein levels are adjusted to protein amount of
2,5mg/mL. The reactionisstarted by adding 400μLo fb u ﬀer
B containing 1mM palmitoyl-CoA (Larodan AB, Malm¨ o,
Sweden) and 10μCi 14C-L-serine (Perkin Elmer, Rodgau-
J¨ ugesheim, Germany) at 37◦C in glass tubes. The reaction is
stopped after 0, 2, 4, 8, 16, 32, and 64min by transferring
500μl of the reaction mixture in glass tubes containing
3,75mL CHCl3 :MeOH:HCl (1:2:0,06). Lipid extraction
was carried out as described above. To measure the radioac-
tivity of the individual sample, 2mL of scintillation liquid
was added to each samples and radioactivity was determined
in a scintillation counter (Perkin Elmer, Rodgau-J¨ ugesheim,
Germany).
2.9. Statistical Analysis. All quantiﬁed data represent an
average of at least three independent experiments. Error
bars represent standard deviation of the mean. Statistical
signiﬁcance was determined by two-tailed Student’s t-test;
signiﬁcance was set at ∗P ≤ .05, ∗∗P ≤ .01, and ∗∗∗P ≤
.001, n.d. = not detectable.
3.Results
3.1. Altered SPT Activity and SPTLC2 Expression in PS1/2-
and APP/APLP2-Deﬁcient Cells. To analyze the inﬂuence of
APP and APP cleavage products on sphingolipid biosynthe-
sis, we used mouse embryonic ﬁbroblasts (MEFs) devoid
of the catalytic components of the γ-secretase complex,
PS1 and PS2 (MEF PS1/2−/−)[ 30, 31], and MEF devoid of
the PS substrate APP and the APP-like protein APLP2 (MEF
APP/APLP2−/−). The common feature of both cell lines is
the lack of Aβ peptides and of AICD. The analysis of the
activity of the key enzyme for the regulation of sphingolipid
levels in cells revealed that the SPT activity was signiﬁcantly
increased in MEF PS1/2−/− and MEF APP/APLP2−/− cells
(Figures 2(a) and 2(b)) compared to the corresponding
control cells. In order to examine if increased SPT activity
is caused by an elevated SPT gene expression, we performed
real-time PCR (RT-PCR) analysis of the corresponding cell
lines. Mammalian SPT is a heterodimer of two subunits, the
53kDa subunit long chain base 1 (SPTLC1 or LCB1) and
the 63kDa subunit long chain base 2 (SPTLC2 or LCB2)
[32, 33]. Gene expression of the subunit SPTLC1 was not
altered in PS1/2−/− cells compared to control cells, whereas
gene transcription of the subunit SPTLC2 was signiﬁcantly
increased in PS1/2-deﬁcient cells (Figure 2(c)). Interestingly,
SPTLC2isconsideredtoberesponsibleforthecatalyticactiv-
ity of SPT [32, 34], indicating that the deﬁciency of PS1/2
inﬂuences the expression of the catalytic subunit of SPT. A
similar result was obtained for APP/APLP2−/− compared to
wt cells; gene expression of SPTLC1 was unchanged, whereas
SPTLC2 gene transcription was signiﬁcantly increased in
APP/APLP2-deﬁcient cells (Figure 2(d)), suggesting that not
PS itself, but at least one of the cleavage products of APP
regulates SPT gene transcription.
3.2. AICD Regulates SPTLC2 Expression. AICD is discussed
to regulate gene transcription by a mechanism comparable
to the function of the Notch intracellular domain, which
is also released by γ-secretase activity, in gene expression
[35–37]. To elucidate the eﬀect of AICD on SPTLC2 gene
transcription, we analyzed APP knock-in mouse embry-
onic ﬁbroblasts deﬁcient of full-length APP, expressing an
APP construct, that lacks the last 15 aa from the C-
terminus (MEF APP
￿CT15) and hence a functional AICD
domain [25], compared to wt cells. Importantly, the deleted
15 aa include the presumably critical YENPTY motif of
APP to which adaptor proteins like Fe65 and X11 are
proposed to bind through their phosphotyrosine-binding
domains and which are responsible for nuclear targeting
of AICD [35, 38, 39]. Indeed, RT-PCR analysis of MEF
APP
￿CT15 cells showed strongly increased gene expres-
sion of the SPT subunit SPTLC2 (Figure 3(a)), indicating
that the presence of a functional AICD domain decreases
SPTLC2 expression. In accordance with increased SPTLC2
expression, SPT activity was signiﬁcantly increased in MEF
APP
￿CT15 cells (Figure 3(a)). To exclude that altered
Aβ production, which might be caused by the truncated
APP construct APP
￿CT15 [40, 41], would be responsi-
ble for increased SPTLC2 expression in MEF APP
￿CT15
cells, we incubated MEF APP
￿CT15 cells with a synthetic
AICD peptide, corresponding to the last 20 aa of the C-
terminus of APP. APP
￿CT15 cells, incubated with sol-
vent control only, showed in comparison to APP
￿CT15
cells incubated with the AICD peptide, increased SPTLC2
expression, emphasizing that AICD decreases SPTLC2 gene
transcription(Figure3(b)).IncubationwithAβpeptidesand4 International Journal of Alzheimer’s Disease
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Figure 2: SPT activity and expression in PS1/2- and APP/APLP2-deﬁcient cells. (a) SPT activity in mouse embryonic ﬁbroblasts devoid of
PS1 and PS2 (MEF PS1/2−/−)a n dM E FP S 1 / 2 −/− retransfected with PS1 (MEF PS1r). (b) SPT activity in mouse embryonic ﬁbroblasts
lackingAPP and the APP-like protein APLP2(MEF APP/APLP2−/−) and corresponding wild-type cells (MEF WT). (c) RT-PCR analysisof
SPTLC1 and SPTLC2 expression, the two subunits of SPT, in MEF PS1/2−/− and MEF PS1r. (d) SPTLC1 and SPTLC2 expression in MEF
APP/APLP2−/− and MEF WT.
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Figure 3: SPTLC2 expression is reduced in the presence of functional AICD. (a) Mouse embryonic ﬁbroblasts expressing an APP construct
lackingthe last15 aminoacids (aa) andtherefore a functional AICD domain(MEF APP
￿CT15) showincreased SPTexpression and activity
compared to control ﬁbroblasts (MEF WT). (b) MEF APP
￿CT15 cells incubated with functional AICD peptide show compared to MEF
APP
￿CT15 cells incubated with solvent control decreased SPTLC2 expression. (c) MEF APP
￿CT15 cells incubated with Aβ peptides and
solvent control showed no diﬀerence in SPTLC2 expression. (d) SPTLC2 expression in Fe65 knock-down SH-SY5Y cells is increased.
solvent control showed no diﬀerences in SPTLC2 expression
(Figure 3(c)), demonstrating that Aβ peptides do not
contribute to the regulation of SPTLC2 gene transcription.
The uptake of the peptides was conﬁrmed by incubating
APP/APLP2−/− MEFs with Aβ peptide. Only in incubated
cells intracellular Aβ could be detected by western blot
analysis whereas the unincubated knockout cells showed
no intracellular Aβ (supplemental Figure 1). To further
evaluate the role of AICD in regulating gene expression
of SPTLC2, we generated Fe65 knock-down human neu-
roblastoma SH-SY5Y cells. RT-PCR of Fe65 showed that
Fe65 expression was reduced to 42%. As expected, the Fe65
knock-down cells had increased SPTLC2 expression (Fig-
ure 3(d)), further emphasizing a physiological role of AICD
in the regulation of SPT expression. Supporting the in vivo
relevance of these ﬁndings, brains of APP knock-out
mice (APP−/−)a sw e l la sb r a i n so fm i c ee x p r e s s i n gt h e
APP
￿CT15 construct had signiﬁcantly increased SPTLC2
expression (Figures 4(a) and 4(b)). Taken together these
results indicate that AICD regulates cellular SPTLC2 gene
transcription in vivo and that this regulation is dependenton
adaptor proteins like Fe65.
3.3. Analysis of SPTLC2 Expression in FAD. In order to
evaluate a potential role of this AICD-mediated regulation
of SPT in AD, we investigated whether familial forms of
Alzheimer’s disease (FAD) show changes in sphingolipidInternational Journal of Alzheimer’s Disease 5
100
∗
S
P
T
e
x
p
r
e
s
s
i
o
n
(
%
o
f
c
o
n
t
r
o
l
)
WT mice brain
APP−/− mice brain
(a)
100
∗∗
S
P
T
e
x
p
r
e
s
s
i
o
n
(
%
o
f
c
o
n
t
r
o
l
)
WT mice brain
APPΔCT15 mice brain
(b)
Figure 4: SPTLC2 expression in APP−/− and APP
￿CT15 mice
brains. (a) SPTLC2 expression in APP-deﬁcient mice brains
(APP−/−) compared to wild-type (wt) mice brains. (b) SPTLC2
expression in APP
￿CT15 mice brains is increased compared to wt
mice brains.
de novo synthesis. For this, MEF cells were generated that
express familial PS1 mutations known to cause early onset
Alzheimer’s disease (EOAD) [42]. MEF PS1/2−/− cells
were retransfected with three PS1-FAD mutations, E280A,
A285V and T354I and wild-type PS1 (MEF PS1r). All
FAD cell lines were PS expression level matched to the
control cells. In accordance to the literature we found that
analysed PS-FAD mutations result in a decreased total γ-
secretase activity (data not shown) and therefore aﬀecting
AICD production [43–48]. RT-PCR analysis revealed that
SPTLC2expressionwassigniﬁcantly increasedinPS1E280A,
PS1 A285V, and PS1 T354I cells, supporting a potential
role of SPT in AD (Figure 5(a)). Although the analysis
of postmortem brain samples allows to draw only limited
conclusions regarding the molecular mechanism, it should
be noted that SPTLC2 expression was increased in familial
AD postmortem brains, caused by the mutations I143T,
L174R and L286V compared to age- and gender-matched
controls (+/− 10 years). Conﬁrming this result, analysis of
postmortem brain samples of 40 sporadic AD brains com-
pared to age- and gender-matched control brains showed
that in 24 cases SPTLC2 expression was increased whereas
in 16 cases SPTLC2 was decreased (Figures 5(b) and 5(c)).
Althoughthemeandiﬀerencebetweenthesporadic ADcases
compared to control brain samples reached signiﬁcant levels
(mean =1,52;P<. 01;SEM =16%)ita ppea r sth a tinf a m ilia l
AD mutations the phenotype of increased SPTLC2 levels has
a higher penetrance.
Although this ﬁnding emphasizes a potential role of
SPT in AD and underlines our ﬁndings made by diﬀerent
cell culture and mouse models, it should be pointed out
that in principal no molecular insights should be drawn
by analyzing human postmortem material. Therefore and to
avoid potential overinterpretation of these results obtained
by postmortem brains we decided not to analyze the AICD
levels.
4.Discussion
Sphingolipids play important roles in biological processes
like regulation of cell growth and signal transduction and
represent ubiquitous constituents of membrane lipids in
eukaryotes [18, 49–51]. Serine-palmitoyl transferase (SPT)
is the rate limiting enzyme that catalyzes the ﬁrst step of de
novo biosynthesis of sphingolipids, ﬁnally resulting in the
synthesis of the three main types of complex sphingolipids:
sphingomyelins, glycosphingolipids, and gangliosides [15].
Alterations in sphingolipid metabolism are discussed to
contribute to the development of AD. Brains of AD patients
show altered ganglioside level [52], elevated ceramide and
sphingosine levels and reduced sphingomyelin levels [14].
Furthermore, gangliosides and sphingomyelin have been
shown to inﬂuence Aβ generation [12, 13]. Sphingolipids
along with cholesterol have been shown to be enriched
in detergent-resistent membrane microdomains, also called
rafts [53–55]. Interestingly, β-a n dγ-secretases are discussed
to be present in rafts [20–24]. Ganglioside GM1 is present in
rafts, increases Aβ generation and has been found to bind to
Aβ [13, 56, 57]. Notably GM1-Aβ is favourably generated in
the ganglioside-enriched, raft-like microdomains and exerts
neurotoxic eﬀects and might act as a seed for Aβ aggregation
in amyloid plaques [56, 58].
Although it is well established that a deregulation of
sphingolipid metabolism is present in AD, the underlying
cellular mechanism that causes changes in sphingolipid
metabolism is poorly understood. It is known that Aβ
increases neutral and acidic sphingomyelinase activity [12,
14] and that expression of acidic sphingomyelinase is
elevated in brains of AD patients [14]. In the present study
we identiﬁed SPT, the rate limiting enzyme in sphingolipid
biosynthesis, to be regulated by APP processing and to
be aﬀected in AD. The ﬁrst indication of increased SPT
activity in AD was obtained by the use of PS1/2- and
APP/APLP2-deﬁcientcell lines, which showed increased SPT
activity. The elevated SPT activity is caused by increased
expression of the SPT subunit SPTLC2, which represents
the catalytic subunit of the SPT heterodimer [32, 34].
Because PS- and APP/APLP2-deﬁcient cells are both devoid
of Aβ and AICD peptides, we analyzed whether these
peptides are responsible for altered SPTLC2 expression.
Analysis of mouse embryonic ﬁbroblasts expressing an APP
construct that lacks a functional AICD domain identiﬁed
AICD as the molecular mediator of decreased SPTLC2 gene
transcription. This result was further substantiated by the
incubation of MEF APP
￿CT15 cells with AICD, resulting
in decreased SPTLC2 expression in presence of AICD. By
partially rescuing the altered SPTLC2 expression with an
AICD peptide incubation, potential artefacts which could
be caused by clonal heterogeneity of MEFs could be ruled
out. Fe65 is an important protein that binds to the YENPTY
motif in the APP C-terminus and is essential for nuclear
transport of AICD [35, 38, 39]. Indeed, Fe65 knock-down
increased SPTLC2 expression, which taken together with
the above results clearly identiﬁes AICD as a regulator of
SPT transcription. AICD was controversially discussed to be
involved in the regulation of gene transcription [35, 38, 39].6 International Journal of Alzheimer’s Disease
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Figure 5:SPTexpression inAlzheimer’s disease.(a)Mouseembryonicﬁbroblastsdevoidof PS1andPS2were retransfected withthe familial
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of SPTLC2 expression in 40 sporadic AD human postmortem brains compared to age- and gender-matched control brains (+/− 10 years).
Pairwise normalizationwith the respective age- and gender-matched controls.
However, increasing evidence exists that AICD regulates
the expression of multiple genes similar to the function of
the Notch intracellular domain. For example, expression of
APP,β-secretase BACE1,neprilysin, EGF-receptor, LRP1and
glycogen-synthase-kinase-3β (GSK-3β) has been shown to
be regulated by AICD [35, 59–62]. Recently, two further
geneswereidentiﬁed,patchedhomolog1(PTCH1)andtran-
sient receptor potential cation channel subfamily C member
5( T R P C 5 )[ 63]. The identiﬁcation of SPTLC2 expression to
be regulated by AICD also contributes to our understanding
of altered sphingolipid levels in AD. SPTLC2 expression was
increased in cells expressing PS mutations known to cause
EOADandinhumanPS-FADpostmortembrains,supporting
the relevance of altered SPT expression and activity in the
development of AD. Taking into consideration that elevated
SPT expression results in increased de novo synthesis of
sphingolipids, major components of lipid rafts, one might
speculate that increased SPTLC2 expression exerts its toxic
eﬀect by increased Aβ generation in lipid raft microdomains
ofthemembrane,knowntobeinvolvedintheamyloidogenic
processing of APP. Nevertheless further experiments have to
be done to clarify the question whether the observed change
in SPTLC2 levels in the human sporadic and familiar AD
brains are cause or consequence of Alzheimer’s disease.
5.Conclusions
In conclusion, our results demonstrate that APP processing
downregulates SPT expression, the rate limiting enzyme in
sphingolipid de novo synthesis by an AICD/Fe65-mediated
mechanism and that SPT expression is aﬀected in AD.
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